Future research should focus on addressing: 1) the association between the spatiotemporal dynamic expression of Hes1 and tumor heterogeneity; 2) the molecular basis of its synergistic effects with driver mutations such as KRAS/EGFR; 3) the development of combination therapy strategies based on the Hes1 signaling node. This evidence concerns the gene KRAS and neoplasm.